InsidersTradesSigma
Total declarations
Company
▲ Purchases (3 ops.)
▼ Sales (3 ops.)
Browse the detailed record of transactions filed by Christian GRENIER, Président du Conseil d’administration de genOway. Insider active across 1 companies, notably GENOWAY. Cumulatively, 6 reports have been published. Total volume traded: €126k. The latest transaction was filed on 15 December 2023 — Cession. Regulator: AMF. The full history is accessible without signup.
Declarations6 total
€22,0005,000 shares@ €4.400.064% mcap29.6% of flow
ActionEuronext Growth Paris
2023DD942884·
€20,0005,000 shares@ €4.000.058% mcap26.9% of flow
ActionEuronext Paris
2023DD929353·
Ideal exit: 21 Jun 2024 (T+270)
€9,2752,500 shares@ €3.710.027% mcap12.5% of flow
ActionEuronext Growth Paris
2023DD894321·
€3210 shares@ €3.200.0001% mcap0.0% of flow
ActionEuronext Growth Paris
2022DD853411·
Ideal exit: 16 Apr 2023 (T+270)
€52,00012,500 shares@ €4.160.15% mcap100.0% of flow
ActionEuronext Growth Paris
2022DD816763·
Ideal exit: 1 Jul 2022 (T+270)
€23,1005,000 shares@ €4.620.067% mcap31.0% of flow
ActionEuronext Growth Paris
2021DD798468·
6 of 6 declarations
About Christian GRENIER
Christian Grenier is a seasoned French corporate governance figure, with extensive experience in listed companies and the life sciences sector. He currently serves as Chairman of the Board of genOway, a Lyon-based company listed on Euronext Growth and specialized in genetically engineered preclinical models. His long association with genOway also includes a prior period as Chairman and Chief Executive Officer, before the company transitioned to a governance structure separating board leadership from executive management. Educated at ESCP and INSEAD, Grenier began his career at McKinsey & Co as a strategy consultant. From 1987 onward, he successively led four subsidiaries of the Rhône-Poulenc Aventis Group, gaining broad operational and international leadership experience. He later co-founded Urogène, a biotechnology company that was sold seven years later to Pierre Fabre, demonstrating an early ability to build and exit an innovation-driven business. Grenier has also played an important role in the French and European life sciences ecosystem. He led the Biovision International Forum in Lyon for five years, bringing together leading scientists, industrial executives, and public decision-makers, while also serving as an operating partner at Advent International in the pharma-chemicals field. Over time, he has held board or supervisory board positions at several biotechnology companies, including Neorphys, Cytomix System, and Watchfrog, and he is currently a board member of Delpharm. This background reflects deep expertise in governance, strategic oversight, industry transformation, and corporate development. At genOway, Grenier has been closely associated with the company’s strategic repositioning toward higher-margin activities and with the execution of its long-term growth roadmap. Recent company disclosures and financial communications highlight his role in board leadership, shareholder value creation, and support for the company’s scientific and commercial expansion. His profile combines strategic thinking, board-level discipline, and a strong understanding of biotechnology markets, making him a key figure in genOway’s corporate governance.
